Published in Curr Opin Mol Ther on April 01, 2010
HIV Vaccine Trial in Thai Adults | NCT00223080
Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women | NCT00442910
Safety of Acidform Lubricant in HIV-Uninfected Women | NCT00850837
Botswana Study of UC-781 Vaginal Microbicide | NCT00385554
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States | NCT00799058
Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem (2010) 0.92
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV. Infect Dis Obstet Gynecol (2014) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Strategies for silencing human disease using RNA interference. Nat Rev Genet (2007) 5.19
Glycerol monolaurate prevents mucosal SIV transmission. Nature (2009) 5.02
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A (2008) 4.53
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Inhibition of respiratory viruses by nasally administered siRNA. Nat Med (2004) 3.69
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol (2009) 3.66
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Human immunodeficiency virus type 1 escape from RNA interference. J Virol (2003) 3.01
Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry. J Virol (1998) 3.00
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 2.62
Mutations of PVRL1, encoding a cell-cell adhesion molecule/herpesvirus receptor, in cleft lip/palate-ectodermal dysplasia. Nat Genet (2000) 2.39
siRNA and innate immunity. Oligonucleotides (2009) 2.28
Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol (2003) 2.26
Connexin-specific cell-to-cell transfer of short interfering RNA by gap junctions. J Physiol (2005) 2.12
Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther (2008) 2.06
Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther (2008) 2.02
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis (2010) 2.00
Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ (2004) 1.95
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe (2009) 1.90
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother (2004) 1.69
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol (2005) 1.68
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun (2006) 1.63
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. Mol Ther (2007) 1.63
RNA interference: a mammalian SID-1 homologue enhances siRNA uptake and gene silencing efficacy in human cells. Biochem Biophys Res Commun (2005) 1.62
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother (2009) 1.60
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 1.54
Striking similarity of murine nectin-1alpha to human nectin-1alpha (HveC) in sequence and activity as a glycoprotein D receptor for alphaherpesvirus entry. J Virol (2000) 1.53
Engineering mucosal RNA interference in vivo. Mol Ther (2006) 1.43
Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob Agents Chemother (2008) 1.43
Replication-defective viruses as vaccines and vaccine vectors. Virology (2006) 1.34
Herpes simplex virus. Front Biosci (2002) 1.32
RNAi mechanisms and applications. Biotechniques (2008) 1.30
Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene (2006) 1.18
VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine (2007) 1.04
Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol (2009) 1.01
Aptamers and aptamer targeted delivery. RNA Biol (2009) 1.00
Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. J Invest Dermatol (2009) 0.99
Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS (2002) 0.96
Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol (2009) 0.88
Towards a durable RNAi gene therapy for HIV-AIDS. Expert Opin Biol Ther (2009) 0.87
CCR5 monoclonal antibodies for HIV-1 therapy. Curr Opin HIV AIDS (2009) 0.87
HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine "success". Science (2009) 0.80
The development and future of oligonucleotide-based therapies for cervical cancer. Curr Opin Mol Ther (2007) 0.77
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe (2009) 1.90
Homeostatic T cell proliferation in a T cell-dendritic cell coculture system. Proc Natl Acad Sci U S A (2002) 1.17
Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J Immunol (2005) 1.16
A general RNA motif for cellular transfection. Mol Ther (2012) 0.94
A peptide that antagonizes TCR-mediated reactions with both syngeneic and allogeneic agonists: functional and structural aspects. J Immunol (2004) 0.87
Optimizing siRNA delivery to the genital mucosa. Discov Med (2011) 0.86
Distinct cathepsins control necrotic cell death mediated by pyroptosis inducers and lysosome-destabilizing agents. Cell Cycle (2015) 0.77
How do cultured CD8(+) murine T cell clones survive repeated ligation of the TCR? Int Immunol (2002) 0.75